EGFR and non-small cell lung carcinoma: For example, patients with NSCLC who harbored epidermal growth factor receptor (EGFR) mutations benefited from EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib [3, 4].